Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesOlecranon bursitis in patients treated with sunitinib for renal cell carcinoma
Medical Oncology, 05/19/09
Gregory T et al. - In a report of 2 cases of pts with metastatic renal cell cancer (RCC) who developed olecranon bursitis while receiving sunitinib, the pathophysiology of this event remains unexplained, although some hypotheses are described.
Methods- Sunitinib is a recently approved tyrosine-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR).
- In both cases, other causes of bursitis were excluded and symptoms resolved after treatment with sunitinib was discontinued.
- Recurrence of symptoms during subsequent treatment cycles was observed.
- This adverse event has not been previously reported for sunitinib and it is believed to be directly attributable to the drug.
- This is an unexpected adverse event, given the mechanism of action of the drug.
Related Articles
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Journal of Clinical Oncology, 11/24/09
Relevance Score: 89%
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer
Medical Oncology, 12/17/09
Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4?,5-trimethoxylstilbene-3?-O-phosphate disodium (M410)
Investigational New Drugs, 12/17/09
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
Investigational New Drugs, 12/17/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension
Human Pathology, 12/19/09
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas
Annals of Diagnostic Pathology, 12/19/09
Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence
Medical Oncology, 12/17/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk analysis of severe myelotoxicity with temozolomide: The effects of clinical and genetic factors
Neuro-Oncology, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/16/09
A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL)
Cancer, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor